Therapeutics in Cardiology: Developments in Cardiovascular Medicine, cartea 81
Editat de Antonio Bayés de Luna, A. Betriu, G. Permanyeren Limba Engleză Paperback – 19 oct 2011
Din seria Developments in Cardiovascular Medicine
- 5% Preț: 1484.50 lei
- 5% Preț: 375.17 lei
- 5% Preț: 354.10 lei
- 5% Preț: 1365.22 lei
- 5% Preț: 362.28 lei
- 5% Preț: 1056.66 lei
- 5% Preț: 1383.84 lei
- 5% Preț: 362.63 lei
- 5% Preț: 354.53 lei
- 5% Preț: 365.97 lei
- 5% Preț: 2037.17 lei
- 5% Preț: 353.48 lei
- 5% Preț: 352.79 lei
- 5% Preț: 357.17 lei
- 5% Preț: 357.01 lei
- 5% Preț: 753.57 lei
- 5% Preț: 686.22 lei
- 5% Preț: 1056.66 lei
- 5% Preț: 361.39 lei
- 5% Preț: 359.45 lei
- 5% Preț: 696.56 lei
- 5% Preț: 1062.27 lei
- 5% Preț: 2036.81 lei
- 5% Preț: 689.01 lei
- 5% Preț: 358.05 lei
- 5% Preț: 695.02 lei
- 5% Preț: 635.16 lei
- 5% Preț: 361.23 lei
- 5% Preț: 1369.25 lei
- 5% Preț: 688.32 lei
- 5% Preț: 760.80 lei
- 5% Preț: 693.42 lei
- 5% Preț: 3064.43 lei
- 5% Preț: 1364.49 lei
- 5% Preț: 754.97 lei
- 5% Preț: 687.61 lei
- 5% Preț: 356.81 lei
- 5% Preț: 362.08 lei
- 5% Preț: 635.88 lei
- 5% Preț: 354.53 lei
Preț: 376.51 lei
Preț vechi: 396.32 lei
-5% Nou
Puncte Express: 565
Preț estimativ în valută:
72.05€ • 76.20$ • 60.10£
72.05€ • 76.20$ • 60.10£
Carte tipărită la comandă
Livrare economică 30 decembrie 24 - 13 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789401070942
ISBN-10: 9401070946
Pagini: 708
Ilustrații: 700 p.
Dimensiuni: 155 x 235 x 37 mm
Greutate: 0.98 kg
Ediția:Softcover reprint of the original 1st ed. 1988
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9401070946
Pagini: 708
Ilustrații: 700 p.
Dimensiuni: 155 x 235 x 37 mm
Greutate: 0.98 kg
Ediția:Softcover reprint of the original 1st ed. 1988
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Severe Arrhythmias and Sudden Death.- 1.1 Introduction.- 1.2 Influence of circadian rhythm on the electrophysiological properties of the human heart.- 1.3 Sudden arrhythmic death - picture of the possible candidate.- 1.4 Sudden death in cardiomyopathies.- 1.5 Sudden death in the Wolff-Parkinson-White syndrome.- 1.6 Conclusions.- 2. The Pharmacological Treatment of Severe Arrhythmias.- 2.1 Introduction.- 2.2 Torsades de pointe.- 2.3 Non-invasive assessment of antiarrhythmic drugs.- 2.4 An electrophysiological approach to drug therapy of ventricular arrhythmias.- 2.5 Application of plasma level determinations to antiarrhythmic drug management.- 2.6 Amiodarone as drug of first choice in the prevention of sustained ventricular tachycardia (VT) and/or ventricular fibrillation (VF).- 2.7 Conclusions.- 3. The Surgical Treatment of the Arrhythmias.- 3.1 Introduction.- 3.2 The role of left stellectomy in the prevention of lethal arrhythmias.- 3.3 Surgical treatment of the cardiac arrhythmias.- 3.4 Early experience in endocardial fulguration for the treatment of ventricular tachycardia.- 3.5 The implantable cardioverter-defibrillator.- 3.6 Conclusions.- 4. Pacemakers.- 4.1 Introduction.- 4.2 Electrophysiological studies in patients with syncope of unknown cause.- 4.3 Tachylog P43 in the control of tachyarrhythmias.- 4.4 Control of the pacemaker patient.- 4.5 Conclusions.- 5. Arterial Hypertension.- 5.1 Introduction.- 5.2 The value of treatment in the prevention of hypertension complications.- 5.3 Use of ?-adrenergic blocking agents in arterial hypertension.- 5.4 Other antihypertensive drugs.- 5.5 Problems in the treatment of chronic primary arterial hypertension.- 5.6 Conclusions.- 6. Heart Failure.- 6.1 Introduction.- 6.2 Patients with heart failure and normal sinus rhythm:who should receive digitalis?.- 6.3 Vasodilators in the treatment of congestive heart failure.- 6.4 The new inotropic agents.- 6.5 Right ventricular failure in ischaemic heart disease.- 6.6 Conclusions.- 7. Heart-Lung Transplantation.- 7.1 Introduction.- 7.2 Transplantation of the heart and lungs.- 7.3 Heart transplantation.- 8. Valvulopathies.- 8.1 Introduction.- 8.2 Bioprosthesis versus mechanical devices.- 8.3 Conservative mitral valve surgery.- 8.4 Chronic valvular heart disease: timing of surgery.- 8.5 Diagnosis of prosthetic dysfunction by means of echocardiography and Doppler ultrasound.- 8.6 Conclusions.- 9. Surgical Correction of Tetralogy of Fallot: Mid-Term Results.- 9.1 Introduction.- 9.2 Mid-term postoperative cardiac catheterization studies after corrective surgery for tetralogy of Fallot.- 9.3 Mid- and long-term postoperative results of tetralogy of Fallot cases operated on in the Hospital Infantil, Ciudad Sanitaria ‘Vall d’Hebron’ (1971–1983).- 9.4 Cardiac dysrhythmias after surgical treatment of tetralogy of Fallot.- 9.5 Tetralogy of Fallot: present status of corrective surgery and midterm follow-up.- 10. Angina Pectoris (I).- 10.1 Introduction.- 10.2 Coronary reserve and angina therapy.- 10.3 Nitrates in the treatment of angina pectoris.- 10.4 Comparison of four calcium antagonists with placebo and propranolol.- 10.5 Pathophysiology of unstable angina pectoris: clinical, angiographic and therapeutic observations.- 10.6 Treatment of primary angina.- 10.7 Conclusions.- 11. Angina Pectoris (II): Instrumental Procedures.- 11.1 Introduction.- 11.2 Current status of coronary angioplasty in Spain.- 11.3 Coronary angioplasty: a new way to revascularization of the heart.- 11.4 Long-term results of coronary artery bypass graft surgery: experience of theMontreal Heart Institute.- 11.5 The Netherlands coronary surgery study (N.C.S.): coronary bypass surgery in patients with mild angina pectoris.- 11.6 Laser treatment of coronary artery disease.- 11.7 Conclusions.- 12. Myocardial Infarction (I).- 12.1 Introduction.- 12.2 Recanalization of coronary arteries by thrombolytic agents in acute myocardial infarction.- 12.3 Rupture of the free ventricular wall during the acute phase of myocardial infarction: diagnosis and treatment.- 12.4 Myocardial revascularization with acute myocardial infarction.- 12.5 Twenty-five years of Coronary Units: perspectives for the future.- 12.6 Thrombolysis in acute myocardial infarction.- 12.7 Conclusions.- 13. Myocardial Infarction (II): Primary and Secondary Prevention.- 13.1 Introduction.- 13.2 How, when and who to treat for dyslipemia.- 13.3 Prophylactic ?-blocking treatment after myocardial infarction.- 13.4 Criticism of long-term preventive treatment after myocardial infarction.- 13.5 Strategies for postinfarction treatment.- 13.6 Conclusions.- Index of Subjects.